1 completed, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Recurrent Primary Peritoneal Serous Adenocarcinoma: new trials by email Literature Review of Recurrent Primary Peritoneal Serous Adenocarcinoma trials Research Report on Recurrent Primary Peritoneal Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
Cystadenocarcinoma, Serous (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma (1) · Cystadenocarcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms by Histologic Type (1)
Bevacizumab (1) · Disulfides (1) · Doxorubicin (1) · Immunoglobulin G (1) · Letrozole (1) · Paclitaxel (1) · Tamoxifen (1) · Taxes (1) · Topotecan (1) · liposomal doxorubicin (1) · pembrolizumab (1) · trametinib (1)
National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1)
United States (2) · United Kingdom (1)
David M Gershenson (1) · Emese Zsiros (1)
P50CA083639 (1), U10CA180868 (1)